Weight-based heparin dosing: Clinical response and resource utilization

Clinical Therapeutics

Volumn 20, Issue 4, 1998, Pages 699-710

  Lackie, Cynthia L ^a,b   Luzier, Aileen B ^a,b   Donovan, John A ^b   Feras, Hawari I ^b   Forrest, Alan ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Millard Fillmore Hospitals   (United States)

Author keywords

Administration and dosage; Anticoagulants, administration and dosage; Clinical practice nomograms; Heparin; Resource utilization; Thrombosis

Indexed keywords

HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; RESOURCE MANAGEMENT; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 0031690335     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80133-1     Document Type: Article

References (22)

1. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. NEJM. 1986;315:1109-1114.
2. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based dosing nomogram compared with a standard care nomogram. Ann Intern Med. 1993;119:874-881.
3. Wheeler AP, Jaquiss RB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Arch Intern Med. 1988;148:1321-1325.
4. Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. Br J Med. 1985;290:27-28.
5. Cipolle RJ, Seifert RD, Neilan BA, et al. Heparin kinetics: Variables related to disposition and dosage. Clin Pharmacol Ther. 1981;29:387-393.
6. Gunnarsson MS, Sawyer WT, Montague D, et al. Appropriate use of heparin. Empiric vs. nomogram-based dosing. Arch Intern Med. 1995;155:526-532.
7. Rivey MP, Peterson JP. Pharmacy-managed, weight-based heparin protocol. Am J Hosp Pharm. 1993;50:279-284.
8. Shalansky KF, Fitzgerald JM, Sunderji R, et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy. 1996;16:1076-1084.
9. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1989;95(Suppl):37S-51S.
10. Abernathy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet. 1986;11:199-213.
11. Cipolle RJ, Rodvold KA. Heparin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. 3rd ed, vol 30. Vancouver, Canada: Applied Therapeutics; 1992:1-39.
12. Nemeth JS, Marxen TL, Piltz GW. Weight-based protocol for improving heparin therapy. Am J Health Syst Pharm. 1996;53: 1164-1166.
13. Campbell NR, Hull RD, Brandt R, et al. Aging and heparin-related bleeding. Arch Intern Med. 1996;156:857-860.
14. De Swart CA, Nijmeyer B, Roelofs JM, et al. Kinetics of intravenously administered heparin in normal humans. Blood. 1982; 60:1251-1258.
15. Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm. 1986;20: 964-967.
16. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992;152:1589-1595.
17. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation. 1996;93:870-878.
18. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
19. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA. 1980; 244:1209-1212.
20. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 1995; 108(Suppl):258S-275S.
21. Schlict JR, Sunyecz L, Weber RJ, et al. Reevaluation of a weight-based heparin dosing nomogram: Is institution-specific modification necessary? Ann Pharmacother. 1997;31:1454-1459.
22. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med. 1997;157:2475-2479.